MSB-0254 is a human monoclonal antibody (mAb) that targets VEGFR2/KDR/CD309. It inhibits the invasion, migration, and vasculogenic mimicry (VM) formation of U251 and primary glioma cells. Additionally, MSB-0254 suppresses the growth of U251 and GL261 cell-transplanted tumors. It reduces the expression of CD34, VEGFR2, Ki67, MMP2, MMP9, and CD34/PAS. MSB-0254 is applicable to research on advanced solid tumors.
Target-Kategorie:
VEGFR
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten